Pituitary

, Volume 5, Issue 2, pp 83–88 | Cite as

Medical Management of Thyrotropin-Secreting Pituitary Adenomas

  • Paolo Beck-Peccoz
  • Luca Persani

Abstract

Thyrotropin-secreting pituitary tumors (TSH-omas) are a rare cause of hyperthyroidism and account for less than 1% of all pituitary adenomas. It is however noteworthy that the number of reported cases tripled in the last years as a consequence of the routine use of ultrasensitive immunometric assays for measuring TSH levels. Contrary to previous RIAs, ultrasensitive TSH assays allow a clear distinction between patients with suppressed and those with non-suppressed circulating TSH concentrations, i.e. between patients with primary hyperthyroidism (Graves' disease or toxic nodular goiter) and those with central hyperthyroidism (TSH-oma or pituitary resistance to thyroid hormone action). Failure to recognize the presence of a TSH-oma may result in dramatic consequences, such as improper thyroid ablation that may cause the pituitary tumor volume to further expand. The medical treatment of TSH-omas mainly rests on the administration of somatostatin analogs, such as octreotide and lanreotide. In fact, administration of dopamine agonists failed to persistently block TSH secretion in almost all patients and caused tumor shrinkage only in those with combined hypersecretion of TSH and PRL. On the contrary, somatostatin analogs were effective in reducing TSH and α-subunit secretion in more than 90% of cases with consequent normalization of FT4 and FT3 levels and restoration of the euthyroid state in the majority of them. In about one third of patients, a clear shrinkage of tumor mass and vision improvement could be demonstrated. Tachyphylaxis, cholelithiasis and carbohydrate intolerance occurred in a minority of treated patients. Whether somatostatin analog treatment may be an alternative to surgery and/or irradiation in patients with TSH-oma remains to be established. Nonetheless, the long-acting somatostatin preparations represent a useful tool for long-term treatment of such a rare pituitary tumors.

TSH-secreting pituitary adenomas (TSH-omas) thyrotropin (thyroid stimulating hormone, TSH) glycoprotein hormone α-subunit (α-GSU) somatostatin analogs (octreotide, lanreotide) dopaminergic drugs (cabergoline, bromocriptine) 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Beck-Peccoz P, Brucker-Davis F, Persani L, Smallridge RC, Weintraub BD. Thyrotropin-secreting pituitary tumors. Endocr Rev 1996;17:610–638.Google Scholar
  2. 2.
    Beck-Peccoz P, Persani L. TSH-producing adenomas. In: DeGroot LJ, Jameson JL, eds. Endocrinology, 4th edn., W.B. Saunders Publisher, 2000:321-328.Google Scholar
  3. 3.
    Jailer JW, Holub DA. Remission of Graves' disease following radiotherapy of a pituitary neoplasm. Am J Med 1960;28:497–500.Google Scholar
  4. 4.
    Hamilton C, Adams LC, Maloof F. Hyperthyroidism due to thyrotropin-producing pituitary chromophobe adenoma. N Engl J Med 1970;283:1077–1080.Google Scholar
  5. 5.
    Refetoff S, Weiss RE, Usala SJ. The syndromes of resistance to thyroid hormone. Endocr Rev 1993;14:348–399.Google Scholar
  6. 6.
    Chatterjee VKK, Clifton-Bright RJ, Gurnell M. Thyroid hormone resistance. In: Jameson JL, ed. Contemporary Endocrinology: Hormone Resistance Syndromes. Totowa, NJ: Humana Press, 1999:145–153.Google Scholar
  7. 7.
    Beck-Peccoz P, Mannavola D, Persani L. Syndromes of thyroid hormone resistance due to mutations in the T3? receptor: Progress in our understanding. Curr Opin Endocrinol Diabetes 2000;7:281–287.Google Scholar
  8. 8.
    Beck-Peccoz P, Piscitelli G, Amr S, Ballabio M, Bassetti M, Giannattasio G, Spada A, Nissim M, Weintraub BD, Faglia G. Endocrine, biochemical, and morphological studies of a pituitary adenoma secreting growth hormone, thyrotropin (TSH), Medical Management of TSH-Omas and ?-subunit: Evidence for secretion of TSH with increased bioactivity. J Clin Endocrinol Metab 1986;62:704–711.Google Scholar
  9. 9.
    Losa M, Giovanelli M, Persani L, Mortini P, Faglia G, Beck-Peccoz P. Criteria of cure and follow-up of central hyperthyroidism due to thyrotropin-secreting pituitary adenomas. J Clin Endocrinol Metab 1996;81:3086–3090.Google Scholar
  10. 10.
    Abs R, Stevenaert A, Beckers A. Autonomously functioning thyroid nodules in a patient with a thyrotropin-secreting pituitary adenoma: Possible cause-effect relationship. Eur J Endocrinol 1994;131:355–358.Google Scholar
  11. 11.
    Kishida M, Otsuka F, Kataoka H, Yokota K, Oishi T, Yamauchi T, Doihara H, Tamiya T, Mimura Y, Ogura T, Makino H. Hyperthyroidism in a patient with TSH-producing pituitary adenoma coexisting with thyroid papillary adenocarcinoma. Endocr J 2000;47:731–738.Google Scholar
  12. 12.
    Gasparoni P, Rubello D, Persani L, Beck-Peccoz P. Unusual association between a thyrotropin-secreting pituitary adenoma and a papillary thyroid carcinoma. Thyroid 1998;8:181–183.Google Scholar
  13. 13.
    Gesundheit N, Petrick P, Nissim M, Dahlberg PA, Doppman L, Emerson CH, Braverman LE, Oldfield EH, Weintraub BD. Thyrotropin-secreting pituitary adenomas: Clinical and biochemical heterogeneity. Ann Intern Med 1989;111:827–835.Google Scholar
  14. 14.
    Sy ARG, Bernstein R, Chynn KI, Kourides IA. Reduction in size of a thyrotropin and gonadotropin-secreting pituitary adenoma treated with octreotide acetate (somatostatin analogue). J Clin Endocrinol Metab 1992;74:690–694.Google Scholar
  15. 15.
    Terzolo M, Orlandi F, Bassetti M, Medri G, Paccotti P, Cortelazzi D, Angeli A, Beck-Peccoz P. Hyperthyroidism due to a pituitary adenoma composed of two different cell types, one secreting alpha-subunit alone and another cosecreting alpha-subunit and thyrotropin. J Clin Endocrinol Metab 1991;72:415–421.Google Scholar
  16. 16.
    Beck-Peccoz P, Persani L, Faglia G. Glycoprotein hormone ?-subunit in pituitary adenomas. Trends Endocrinol Metab 1992;3:41–45.Google Scholar
  17. 17.
    Brucker-Davis F, Oldfield EH, Skarulis MC, Doppman JL, Weintraub BD. Thyrotropin-secreting pituitary tumors: Diagnostic criteria, thyroid hormone sensitivity, and treatment outcome in 25 patients followed at the National Institutes of Health. J Clin Endocrinol Metab 1999;84:476–486.Google Scholar
  18. 18.
    Beck-Peccoz P, Roncoroni R, Mariotti S, Medri G, Marcocci C, Brabant G, Forloni F, Pinchera A, Faglia G. Sex hormone-binding globulin measurement in patients with inappropriate secretion of thyrotropin (IST): Evidence against selective pituitary thyroid hormone resistance in nonneoplastic IST. J Clin Endocrinol Metab 1990;71:19–25.Google Scholar
  19. 19.
    Persani L, Preziati D, Matthews CH, Sartorio A, Chatterjee VK, Beck-Peccoz P. Serum levels of carboxyterminal cross-linked telopeptide of type I collagen (ICTP) in the differential diagnosis of the syndromes of inappropriate secretion of TSH. Clin Endocrinol 1997;47:207–214.Google Scholar
  20. 20.
    Bonomi M, Proverbio MC, Weber G, Chiumello G, Beck-Peccoz P, Persani L. Hyperplastic pituitary gland, high serum glycoprotein hormone alpha-subunit, and variable circulating thyrotropin (TSH) levels as hallmark of central hypothyroidism due to mutations of the TSH beta gene. J Clin Endocrinol Metab 2001;86:1600–1604.Google Scholar
  21. 21.
    Losa M, Magnani P, Mortini P, Persani L, Acerno S, Giugni E, Fazio F, Beck-Peccoz P, Giovanelli M. Indium-111 pentetreotide single-photon emission tomography in patients with TSH-secreting pituitary adenomas: Correlation with the effect of a single administration of octreotide on serum TSH levels. Eur J Nucl Med 1997;24:728–731.Google Scholar
  22. 22.
    Bertherat J, Brue T, Enjalbert A, Gunz G, Rasolonjanahary R, Warnet A, Jaquet P, Epelbaum J. Somatostatin receptors on thyrotropin-secreting pituitary adenomas: Comparison with the inhibitory effects of octreotide upon in vivo and in vitro hormonal secretions. J Clin Endocrinol Metab 1992;75:540–546.Google Scholar
  23. 23.
    Cooper DS, Wenig BM. Hyperthyroidism caused by an ectopic TSH-secreting pituitary tumor. Thyroid 1996;6:337–343.Google Scholar
  24. 24.
    Molitch ME, Russell EJ. The pituitary "incidentaloma." Ann Intern Med 1990;112:925–931.Google Scholar
  25. 25.
    Webster J, Peters JR, John R, Smith J, Chan V, Hall R, Scanlon MF. Pituitary stone: Two cases of densely calcified thyrotropin-secreting pituitary adenomas. Clin Endocrinol 1994;40:137–143.Google Scholar
  26. 26.
    Ezzat S, Horvath E, Kovacs K, Smyth HS, Singer W, Asa SL. Basic fibroblast growth factor expression by two prolactin and thyrotropin-producing pituitary adenomas. Endocr Pathol 1995;6:125–134.Google Scholar
  27. 27.
    Trouillas J, Girod C, Loras B, Claustrat B, Sassolas G, Perrin G, Buonaguidi R. The TSH secretion in the human pituitary adenomas. Pathol Res Pract 1988;183:596–600.Google Scholar
  28. 28.
    Ohki M, Sato K, Tuchiya D, Sato S, Saito S, Kinjo T, Kayama T, Yokura H, Yoshimoto T. A case of TSH-secreting pituitary adenoma associated with an unruptured aneurysm: Successful treatment by two-stage operation and gamma knife. No To Shinkei 1999;51:895–899.Google Scholar
  29. 29.
    Gancel A, Vuillermet P, Legrand A, Catus F, Thomas F, Kuhn JM. Effets of a slow-release formulation of the new somatostatin analogue lanreotide in TSH-secreting pituitary adenomas. Clin Endocrinol 1994;40:421–428.Google Scholar
  30. 30.
    Kuhn JM, Arlot S, Lefebvre H, Caron P, Cortet-Rudelli C, Archambaud F, Chanson P, Tabarin A, Goth MI, Blumberg J, Catus F, Ispas S, Beck-Peccoz P. Evaluation of the treatment of thyrotropin-secreting pituitary adenomas with a slow release formulation of the somatostatin analog lanreotide. J Clin Endocrinol Metab 2000;85:1487–1491.Google Scholar
  31. 31.
    Caron P, Arlot S, Bauters C, Chanson P, Kuhn JM, Pugeat M, Marechaud R, Teutsch C, Vidal E, Sassano P. Efficacy of the long-acting octreotide formulation (octreotide-LAR) in patients with thyrotropin-secreting pituitary adenomas. J Clin Endocrinol Metab 2001;86:2849–2853.Google Scholar
  32. 32.
    Wood DF, Johnston JM, Johnston DG. Dopamine, the dopamine D2 receptor and pituitary tumours. Clin Endocrinol 1991;35:455–466.Google Scholar
  33. 33.
    Spada A, Bassetti M, Martino E, Giannattasio G, Beck-Peccoz P, Sartorio P, Vallar L, Baschieri L, Pinchera A, Faglia G. In vitro studies on TSH secretion and adenylate cyclase activity in a human TSH-secreting pituitary adenoma. Effects of somatostatin and dopamine. J Endocrinol Invest 1985;8:193–198.Google Scholar
  34. 34.
    Rocheville M, Lange DC, Kumar U, Patel SC, Patel RC, Patel YC. Receptors for dopamine and somatostatin: Formation of hetero-oligomers with enhanced functional activity. Science 2000;288:154–157.Google Scholar
  35. 35.
    Werner S. Human pituitary adenomas with hypersecretion of TSH and prolactin. Evidence that receptor sites for dopamine may be absent on TSH producing while present on prolactin producing cells. Horm Metab Res 1979;11:452–453.Google Scholar
  36. 36.
    Wollesen F, Andersen T, Karle A. Size reduction of extrasellar pituitary tumors during bromocriptine treatment. Quantitation of effect on different types of tumors. Ann Intern Med 1982;96:281–286.Google Scholar
  37. 37.
    Faglia G, Beck-Peccoz P, Piscitelli G, Medri G. Inappropriate secretion of thyrotropin by the pituitary. Horm Res 1987;26:79–99.Google Scholar
  38. 38.
    Scanlon MF, Howells S, Peters JR, Williams ED, Richards S, Hall R, Thomas JP. Hyperprolactinaemia, amenorrhoea and Beck-Peccoz and Persani galactorrhoea due a pituitary thyrotroph adenoma. Clin Endocrinol 1985;23:35–42.Google Scholar
  39. 39.
    Kerstens MN, Kappelle JW, van der Berg G. Partial remission with cabergoline of a thyrotropin producing pituitary tumor cosecreting prolactin. Proceedings of the 84th Annual Meeting of the Endocrine Society. San Francisco, CA, 2002, Abs no. P2-570.Google Scholar
  40. 40.
    Chanson P, Weintraub BD, Harris AG. Octreotide therapy for thyroid stimulating-secreting pituitary adenomas. A follow-up of 52 patients. Ann Intern Med 1993;119:236–240.Google Scholar
  41. 41.
    Adriaanse R, Brabant G, Endert E, Bemelman FJ, Wiersinga WM. Pulsatile thyratropin and prolactin secretion in a patient with a mixed thyrotropin-and prolactin-secreting pituitary adenoma. Eur J Endocrinol 1994;130:113–120.Google Scholar
  42. 42.
    Comi R, Gesundheit N, Murray L, Gorden P, Weintraub BD. Response of thyrotropin-secreting pituitary adenomas to a longacting somatostatin analogue. New Engl J Med 1987;317:12–17.Google Scholar
  43. 43.
    Houdent CH, Armangau MF, Kuhn JM, Delangre T, Tadie M, Clavier E, Basuyau JP, Sassolas G, Wolf LM. Adénome thyréotrope traité par un analogue de la somatostatine. Ann Endocrinol (Paris) 1989;50:227–231.Google Scholar
  44. 44.
    Levy A, Eckland DJA, Gurney AM, Reubi JC, Doshi R, Lightman SL. Somatostatin and thyrotropin-releasing hormone response and receptor status of a thyrotropin-secreting pituitary adenoma: Clinical and "in vitro" studies. J Neuroendocrinol 1989;1:321–326.Google Scholar
  45. 45.
    Caron P, Gerbaud C, Pradayrol L, Simonetta C, Bayard F. Successful pregnancy in an infertile woman with a thyrotropin-secreting macroadenoma treated with somatostatin analog (octreotide). J Clin Endocrinol Metab 1996;81: 1164–1168.Google Scholar
  46. 46.
    Blackhurst G, Strachan MW, Collie D, Gregor A, Statham PFX, Seckl JER. The treatment of a thyrotropin-secreting pituitary macroadenoma with octreotide in twin pregnancy. Clin Endocrinol 2002;56:401–404.Google Scholar

Copyright information

© Kluwer Academic Publishers 2002

Authors and Affiliations

  • Paolo Beck-Peccoz
    • 1
  • Luca Persani
    • 1
  1. 1.Institute of Endocrine Sciences, University of Milan, Ospedale Maggiore IRCCS and Istituto Auxologico Italiano IRCCSMilanItaly

Personalised recommendations